Verastem Inc (NASDAQ:VSTM)‘s stock had its “outperform” rating reiterated by stock analysts at Cann in a report released on Wednesday. They currently have a $6.00 price target on the biopharmaceutical company’s stock. Cann’s target price would indicate a potential upside of 270.37% from the company’s previous close.
A number of other analysts also recently issued reports on the company. HC Wainwright raised their target price on Verastem from $5.00 to $6.50 and gave the stock a “buy” rating in a research note on Friday, March 24th. Cantor Fitzgerald downgraded Verastem from a “buy” rating to a “hold” rating in a research note on Tuesday, January 10th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Verastem currently has a consensus rating of “Buy” and an average target price of $4.08.
Verastem (NASDAQ:VSTM) traded up 19.75% during mid-day trading on Wednesday, hitting $1.94. The company had a trading volume of 894,988 shares. The company’s market capitalization is $71.76 million. Verastem has a 52-week low of $1.05 and a 52-week high of $2.25. The company has a 50-day moving average price of $1.54 and a 200 day moving average price of $1.32.
ILLEGAL ACTIVITY NOTICE: This piece was originally reported by sleekmoney and is owned by of sleekmoney. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://sleekmoney.com/verastem-inc-vstm-receives-new-coverage-from-analysts-at-cann/1738743.html.
A hedge fund recently raised its stake in Verastem stock. FMR LLC increased its position in Verastem Inc (NASDAQ:VSTM) by 32.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 901,200 shares of the biopharmaceutical company’s stock after buying an additional 219,445 shares during the period. FMR LLC owned 2.44% of Verastem worth $1,009,000 as of its most recent filing with the SEC.
Verastem Company Profile
Verastem, Inc is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/verastem-inc-vstm-receives-new-coverage-from-analysts-at-cann/1738743.html
Receive News & Ratings for Verastem Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem Inc and related companies with MarketBeat.com's FREE daily email newsletter.